MAIA Biotechnology (NYSEAMERICAN:MAIA) Issues Earnings Results

MAIA Biotechnology (NYSEAMERICAN:MAIA) posted its quarterly earnings results on Monday. The company reported ($0.08) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.05, FiscalAI reports.

MAIA Biotechnology Stock Performance

NYSEAMERICAN:MAIA traded up $0.06 during trading hours on Wednesday, reaching $1.50. The company’s stock had a trading volume of 174,540 shares, compared to its average volume of 1,050,837. The stock has a 50 day moving average price of $1.93 and a two-hundred day moving average price of $1.58. The company has a market capitalization of $57.99 million, a P/E ratio of -2.17 and a beta of -0.04. MAIA Biotechnology has a 12 month low of $0.87 and a 12 month high of $3.19.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in MAIA. Geode Capital Management LLC boosted its position in shares of MAIA Biotechnology by 3.6% in the 2nd quarter. Geode Capital Management LLC now owns 222,183 shares of the company’s stock worth $400,000 after purchasing an additional 7,746 shares in the last quarter. Marshall Wace LLP purchased a new stake in MAIA Biotechnology in the second quarter valued at about $29,000. Finally, Jane Street Group LLC purchased a new stake in MAIA Biotechnology in the second quarter valued at about $52,000. 5.65% of the stock is owned by institutional investors.

MAIA Biotechnology Company Profile

MAIA Biotechnology, Inc is a clinical?stage biopharmaceutical company developing a proprietary platform for site?specific conjugation of monoclonal antibodies with diagnostic and therapeutic radioisotopes. By leveraging precision radiochemistry, the company aims to enhance the safety and efficacy profiles of antibody?based imaging agents and targeted radiotherapeutics. Its approach is designed to deliver high?contrast tumor visualization through PET imaging as well as focused cytotoxicity in oncology indications.

The company’s pipeline includes several antibody?radiotracer candidates optimized for the detection of distinct tumor biomarkers, with preclinical data showing favorable targeting specificity and improved pharmacokinetics compared to conventional methods.